产品
编 号：F758535
产品类型
规格
价格
是否有货
结构图
CAS No: 502496-16-4
产品详情
生物活性：
Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2.
体内研究：
Urtoxazumab (TMA-15) (0.25-2.5 mg/kg;注射。一次)以时间和剂量依赖的方式改善 B2F1 感染小鼠的致死率。Animal Model:5-week-old male DBA/2J mice, STEC B2F1-infection model
Dosage:0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg
Administration:Intravenous administration, 1 h before and 12, 24, and 48 h after infection
Result:Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.
Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2.
体内研究：
Urtoxazumab (TMA-15) (0.25-2.5 mg/kg;注射。一次)以时间和剂量依赖的方式改善 B2F1 感染小鼠的致死率。Animal Model:5-week-old male DBA/2J mice, STEC B2F1-infection model
Dosage:0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg
Administration:Intravenous administration, 1 h before and 12, 24, and 48 h after infection
Result:Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备